TCT 2021 to Highlight Improved Patient Outcomes with Impella’s Small, Smart and Connected Technology
The robust, high-quality data and clinical studies supporting the use of Abiomed's (NASDAQ:ABMD) Impella heart pumps in high-risk PCI, cardiogenic shock and right heart failure patients will be showcased at Transcatheter Cardiovascular Therapeutics (TCT) 2021, the annual scientific symposium of the Cardiovascular Research Foundation. The conference will meet virtually and in-person in Orlando, Florida, on November 4 – 6.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211101005297/en/
Impella CP with SmartAssist, shown placed in the heart’s left ventricle. (Photo: Business Wire)
Impella heart pumps are the world’s smallest heart pumps. They unload the heart while providing coronary and end organ perfusion. Impella SmartAssist technology enables improved patient outcomes via real-time intelligence. Abiomed augments limited hospital resources by providing 24x7 support on-site, on-call and online.
Throughout TCT, and at a pre-conference workshop on November 3, leading physician-researchers will present data demonstrating:
- Complete revascularization with Impella improves ejection fraction and long-term patient outcomes.
- Cardiogenic shock best practices, including early unloading with Impella pre-PCI and timely escalation to Impella RP and Impella 5.5 with SmartAssist, are associated with improved survival and native heart recovery.
During TCT 2021, physicians will detail final results from two large studies of Impella -- the PROTECT III post approval study and the RESTORE EF study. Interim results from both studies were presented at TCT 2020 and demonstrated the benefits of using contemporary practices to achieve complete revascularization with Impella.
The high-quality clinical evidence being generated from the PROTECT series of studies includes the PROTECT II randomized controlled trial (RCT) and the ongoing PROTECT IV RCT of Impella use in high-risk PCI patients. Based on PROTECT II RCT data, and data from additional robust prospective clinical studies, the United States Food and Drug Administration (FDA) granted Impella premarket approvals (PMA) as safe and effective for high-risk PCI, cardiogenic shock and right heart failure.
TCT presenters will also review the real-world evidence (RWE) and best practices gathered since Impella’s FDA approvals. This evidence will inform the RECOVER IV RCT of Impella use in cardiogenic shock patients. The RWE includes prospective data from the National Cardiogenic Shock Initiative (NCSI) Study, J-PVAD Study and INOVA Study. These datasets demonstrate cardiogenic shock best practices, including early use of Impella, are associated with improved survival rates of 71%, 77% and 82% (respectively), compared to the historical cardiogenic shock survival rate of about 50%.
In-person attendees of TCT 2021 are invited to visit Abiomed at the TCT Industry Hub, which will be open from 8:00 am – 5:30 pm EDT. At the Hub, attendees will be able to participate in hands-on Impella demonstrations, view the newest technologies, talk with members of the Abiomed product development team, and learn the latest information about Abiomed’s ongoing and planned randomized controlled trials.
Virtual attendees of TCT 2021 are invited to participate in three ways:
- Visit www.HeartRecovery.com 24x7 to experience Abiomed’s virtual cath lab and view live and on-demand TCT-related video content.
- Follow the @HeartRecovery and @ProtectedPCI Twitter handles for the latest TCT news and events.
- Tune in for the live TCT recap program, livestreamed on www.HeartRecovery.com at 6:00 pm EDT on Thursday, November 4, and Friday, November 5. Chuck Simonton, MD, and Seth Bilazarian, MD, from the Abiomed medical office will present the top TCT news of the day. After the live broadcast, the program will be available for on-demand viewing.
In-person and virtual participants of TCT are invited to attend a breakfast symposium on Thursday, November 4. The principal investigators of the PROTECT IV RCT, the RECOVER IV RCT and the STEMI Door-to-Unloading RCT will update the physician community on the progress of those trials. The symposium will also review the clinical experience with the new 9 French Impella ECP heart pump. The schedule of presentations and instructions for in-person and virtual viewing are below:
Clinical Science to Landmark Trials of Left Ventricular Unloading in High-Risk PCI and Cardiogenic Shock
Date: Thursday, November 4, 2021
Time: 6:30 – 7:30 am EDT
In-Person Location: Orange County Convention Center, Clinical Science Theater, Level 1, Halls A & B
Virtual Location: Watch via the official TCT 2021 conference livestream
Presenters:
- PROTECT Series Leading to PROTECT IV, Gregg Stone, MD, Mount Sinai Health System, New York City
- Real World Evidence Leading to RECOVER IV, William O’Neill, MD, Henry Ford Hospital, Detroit
- Door to Unload: Implications for STEMI, High-Risk PCI and Cardiogenic Shock, Navin Kapur, MD, Tufts Medical Center, Boston
- Breaking the Small-Bore Barrier: Impella ECP 9 Fr Heart Pump Clinical Experience, Amir Kaki, MD, Ascension St. John Hospital, Detroit
In conjunction with TCT, Abiomed is also hosting a pre-meeting workshop on November 3 for members of CAMP PCI. CAMP PCI (Coronary Artery & Myocardial Protected PCI) is the leading online and in-person physician education platform dedicated to improving patient outcomes and quality of life with supported high-risk PCI by utilizing best practices, techniques and technologies to enable safer, more effective and complete revascularization.
ABOUT IMPELLA HEART PUMPS
The Impella 2.5® and Impella CP® devices are U.S. FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI), such as stenting or balloon angioplasty, to reopen blocked coronary arteries.
The Impella 2.5, Impella CP, Impella CP with SmartAssist®, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005297/en/
Contact information
Media Contact:
Tom Langford
Director of Communications
+1 (978) 882-8408
tlangford@abiomed.com
Investor Contact:
Todd Trapp
Vice President and Chief Financial Officer
+1 (978) 646-1680
ttrapp@abiomed.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Castles Technology Partners With Loomis Pay to Power European Expansion With Next-Generation Android Devices27.1.2026 09:00:00 EET | Press release
Castles Technology, a global leader in Android payment acceptance devices, has been selected by Loomis Pay, the POS and digital payment division of Loomis, to support its European expansion. Through this collaboration, Loomis Pay will strengthen its capacity to deliver flexible and secure POS and payment solutions tailored to merchant preferences. As well as empowering merchants and their customers to transact the way they prefer, cash, card and digital. Following an extensive market review, Loomis Pay chose Castles Technology for its leadership in Android-based payment solutions, recognized for versatility, reliability, and innovation across its latest Android devices. Loomis Pay will deploy their POS and payment services on the portable S1F4 Pro, the PINPAD S1P2 and the unattended S1U2M4, as well its CasHUB TMS and Marketplace. Castles Technology and Loomis Pay have been working hand-in-hand with Seitatech, a specialized Finnish payment expert company, to develop the complete softwar
Cirium Ascend Consultancy Named Appraiser of the Year at the Aviation 100 Awards for a Record 11th Time27.1.2026 08:00:00 EET | Press release
Cirium Ascend Consultancy has been named Appraiser of the Year 2026 in the Airline Economics Aviation 100 Global Leaders Awards, the team’s 11th title in 15 years. The Consultancy is a highly respected division of Cirium, the world’s most trusted source of aviation analytics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126679094/en/ AOTY Win The Appraiser of the Year award recognizes the aircraft appraisal provider that has demonstrated the greatest contribution to the industry over the past year. The fourth consecutive win reflects the trust placed in the Ascend Consultancy team and their work by their industry peers. The Aviation 100 Global Leaders Awards celebrate the best companies, individuals and transactions in the aviation finance and leasing sector. Accolades are awarded based on an industry-wide survey and an expert panel of judges. “Receiving Appraiser of the Year for the 11th time is a meaningful endorsemen
Ohana Development and Manchester City F.C. Sign Agreement to Launch Multi-Billion-Dirham Project in Abu Dhabi27.1.2026 08:00:00 EET | Press release
Ohana Development, a leading UAE real estate developer renowned for its luxury properties, has signed an agreement with Manchester City F.C. to launch ‘Manchester City Yas Residences by Ohana’, a first-of-its-kind branded residential community, set along Abu Dhabi’s Yas Canal waterfront. The partnership reflects a shared commitment to excellence, innovation and long-term value creation, reinforcing Abu Dhabi’s position as a global destination for world-class developments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126122700/en/ Standing: HE Khaldoon Al Mubarak, Chairman of Manchester City Football Club. Left to right: Husein Salem, CEO of Ohana Development and Ferran Soriano, CEO of City Football Group. (Photo: AETOSWire). Spanning 1.67 million square metres, ‘Manchester City Yas Residences by Ohana’ draws on the club’s global appeal and legacy, reimagined through a contemporary lens, aligning Manchester City’s identi
EIB Provides €20 Million in Financing to SamanTree Medical for Real-Time Microscopy for Surgical Procedures27.1.2026 08:00:00 EET | Press release
SamanTree Medical, a European leader in surgical imaging innovation, has secured €20 million in financing from the European Investment Bank (EIB). The operation is backed by InvestEU, the EU’s flagship program to mobilize over €372 billion in additional investment from 2021 to 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126080876/en/ The European Investment Bank (EIB) provides €20 million in financing to SamanTree Medical, a leader in surgical imaging innovation. The financing supports the development of an advanced confocal microscopy scanner for rapid imaging of the internal microstructure of tissue samples during surgical procedures, R&D and continued development and advancement of the company's Histolog® Scanner, the first and only medical imaging device featuring massively parallel confocal microscopy. Shown: Alessandro Izzo, EIB Director (left) and Olivier Delporte, CEO of SamanTree Medical (right). The fin
Access Advance Extends HEVC Advance Rate Increase Deadline27.1.2026 03:00:00 EET | Press release
Access Advance LLC today announced that the Licensors of HEVC Advance have approved an extension of the deadline for new Licensees to secure current royalty rates and caps through 2030. Companies that become Licensees of the HEVC Advance program on or before June 30, 2026 will secure current royalty rates for both ongoing royalties and calculation of royalties for past sales. This is a temporary postponement of the 25% increase in rates and caps applicable to Licensees who sign up after the previous December 31, 2025 deadline. The extension also applies to the Multi-Codec Bridging Agreement ("MCBA"), which provides a single discounted royalty rate structure for Licensees in both the HEVC Advance Patent Pool and the VVC Advance Patent Pool. Licensees who execute the MCBA by June 30, 2026 will benefit from royalty caps that match the royalty caps for the VVC Advance program. The extension follows Access Advance's record 4th Quarter growth in all three main patent pools, a 100% renewal ra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom